SCHEMBL5439738

SCHEMBL5439738

COc1ccc(-c2ccc(=O)n(Cc3cccc(F)c3F)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.45
▸ MKNK1 Q9BUB5 2/20 0.44
▸ MKNK2 Q9HBH9 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ CXCR2 P25025 1/20 0.41
▸ P2RX7 Q99572 1/20 0.41
▸ PTGDR2 Q9Y5Y4 1/20 0.40
▸ SDHB P21912 2/20 0.39
▸ BRD4 O60885 1/20 0.39
▸ PDE10A Q9Y233 1/20 0.38
▸ TP53 P04637 1/20 0.37
▸ ROCK2 O75116 1/20 0.37
▸ MAOB P27338 1/20 0.37
▸ NFKB1 P19838 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5441383 0.90 MAPT (0.57) MAPTMKNK1MKNK2MEN1KMT2A
SCHEMBL5431656 0.81 MAPT (0.55) MAPTMEN1KMT2AALDH1A1TP53
SCHEMBL5442659 0.80 PTGDR2 (0.52) MAPTMKNK1MKNK2MEN1KMT2A
SCHEMBL5433228 0.80 MEN1 (0.54) MAPTMKNK1MKNK2MEN1KMT2A
SCHEMBL5197304 0.78 MAPT (0.49) MAPTMKNK1MKNK2MEN1KMT2A
SCHEMBL5439436 0.78 BRD4 (0.57) MAPTMKNK1MKNK2ALDH1A1P2RX7
SCHEMBL5433988 0.77 SDHB (0.43) MKNK1MKNK2MEN1KMT2ASMN1; SMN2
SCHEMBL5445065 0.77 SDHB (0.54) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5430703 0.76 CNR1 (0.52) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5435658 0.76 SDHB (0.46) MKNK1MKNK2MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS ADDEX PHARMACEUTICALS S.A. (CH) 2013-05-02 — — US claimed
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS ADDEX PHARMACEUTICALS S.A. (CH) 2013-05-02 — — US disclosed
US-8399493-B2 Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors Janssen Pharmaceuticals, Inc. (US) 2013-03-19 — — US disclosed
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS Janssen Pharmaceuticals, Inc. 2007-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRM3 MAPT 2615/4885MKNK1 2293/4885MKNK2 1366/4885
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRIA2 MAPT 2062/4885MKNK1 1868/4885MKNK2 1100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback